Chandler, AZNCT07732400Now EnrollingIRB Ready

Metabolic Dysfunction-associated Steatohepatitis (MASH) Clinical Trial in Chandler, AZ

Access cutting-edge metabolic dysfunction-associated steatohepatitis (mash) treatment through this phase 1/2 clinical trial at a research site in Chandler. Study-provided care at no cost to qualified participants.

Sponsored by Kriya Therapeutics, Inc.

Quick Self-Assessment

See if you qualify for this Chandler location

Preparing your pre-screening questions…

Expert Care in Chandler

Access metabolic dysfunction-associated steatohepatitis (mash) specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related metabolic dysfunction-associated steatohepatitis (mash) treatment provided free

Apply for This Chandler Location

Check if you qualify for this metabolic dysfunction-associated steatohepatitis (mash) clinical trial in Chandler, AZ

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Chandler

    Convenient for AZ residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Chandler site if eligible
  4. 4Begin participation

About This Metabolic Dysfunction-associated Steatohepatitis (MASH) Study in Chandler

A Study of VV-14303 for the Treatment of Metabolic dysfunction-associated steatohepatitis (MASH)

Sponsor: Kriya Therapeutics, Inc.

Who Can Participate

Inclusion Criteria

Participant is capable of providing signed informed consent, which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in the protocol
Must be 18 to 75 years of age (inclusive) at Screening
Body Mass Index (BMI) of 25 to \<40 kg/m2 (inclusive)
Male participants must agree to use a highly effective contraception during the Treatment Period and at least 12 months after administration of VV-14303. Female participants must not be a woman of child-bearing potential (WOCBP)
Biopsy-confirmed MASH
Previous history or presence of ≥2 of the following metabolic risk factors: obesity (BMI ≥25 kg/m²), hypertension (blood pressure \[BP\] ≥140/90 mmHg or on antihypertensive medication), dyslipidemia (triglycerides ≥150 mg/dL or high-density lipoprotein cholesterol \[HDL-C\] \<40 mg/dL in men/\<50 mg/dL in women or on lipid-lowering therapy), type 2 diabetes mellitus
Must be willing to refrain from the donation of blood, plasma, platelets, eggs, or sperm during the 12-month post-treatment follow-up period

Exclusion Criteria

Presence of alternate and/or additional liver disease etiologies at Screening, including but not limited to chronic viral hepatitis, autoimmune hepatitis
Use of treatments for metabolic syndrome management, including oral antidiabetic drugs (OADs) (e.g., metformin), incretin mimetics (GLP-1 receptor agonists or GLP-1/gastric inhibitory polypeptide \[GIP\] agonists) or other glucose-lowering agents that has not been stable for at least 6 months prior to Screening
Use of Resmetirom that has not been stable for at least 6 months prior to Screening visit
Any medical, cognitive, or psychiatric condition that, in the opinion of the Investigator, could contraindicate the use of the investigational drug, make consistent study assessment and follow-up over the 12-month Post-Treatment Follow-up Period unlikely, or would make the participant an unsafe study candidate.
Type 1 diabetes, or poorly controlled type 2 diabetes (HbA1c \> 8.0% at Screening)
History of major trauma to the muscle(s) intended for IM injection meeting any of the following criteria:
Within 6 months prior to Screening, or
At any timepoint prior to Screening with continued neurologic or musculoskeletal symptoms
Prior participation in any systemic experimental treatment or receiving any other systemic investigational treatment including within 6 weeks or 5 half-lives of the active ingredient (whichever is longer) prior to the start of Screening
Any vaccination or planned vaccination 30 days prior to dosing, or planned vaccination 8 weeks post dosing
Previously received AAV or adenoviral therapy or participation in any previous gene therapy trial

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Chandler?

Yes, this clinical trial (NCT07732400) has an active research site in Chandler, AZ that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Metabolic Dysfunction-associated Steatohepatitis (MASH) Treatment Options in Chandler, AZ

If you're searching for metabolic dysfunction-associated steatohepatitis (mash) treatment options in Chandler, AZ, this clinical trial (NCT07732400) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Chandler research site is actively enrolling participants for this phase 1/2 clinical trial. You'll receive care from experienced metabolic dysfunction-associated steatohepatitis (mash) specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all metabolic dysfunction-associated steatohepatitis (mash) clinical trials near you to find additional studies recruiting in your area.

More Essential Tremor Trials in Chandler, AZ

See all essential tremor clinical trials recruiting in Chandler — not just this study.

Browse Essential Tremor Trials in Chandler →

Browse More Trials by Condition

Essential Tremor TrialsAnkylosing Spondylitis TrialsNASH TrialsErectile Dysfunction TrialsInterstitial Cystitis TrialsMyalgic Encephalomyelitis TrialsAll Conditions →

Ready to Join in Chandler?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Chandler, AZ